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Abstract
Background: The anti-HIV-1 neutralizing antibody assay is widely used in AIDS vaccine research
and other experimental and clinical studies. The vital dye staining method applied in the detection
of anti-HIV-1 neutralizing antibody has been used in many laboratories. However, the unknown
factor(s) in sera or plasma affected cell growth and caused protection when the tested sera or
plasma was continuously maintained in cell culture. In addition, the poor solubility of neutral red in
medium (such as RPMI-1640) also limited the use of this assay.
Methods: In this study, human T cell line C8166 was used as host cells, and 3-(4,5-Dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) instead of neutral red was used as vital dye.
In order to avoid the effect of the unknown factor(s), the tested sera or plasma was removed by a
washout procedure after initial 3–6 h culture in the assay.
Result: This new assay eliminated the effect of the tested sera or plasma on cell growth, improved
the reliability of detection of anti-HIV-1 neutralizing antibody, and showed excellent agreement
with the p24 antigen method.
Conclusion: The results suggest that the improved assay is relatively simple, highly duplicable,
cost-effective, and well reliable for evaluating anti-HIV-1 neutralizing antibodies from sera or
plasma.
Background
The increasing spread of HIV-1 pandemic around world,
especially in developing countries, is severely threatening
human health. Neutralizing antibody (NAb) [1,2] and
cytotoxic T lymphocyte (CTL) [3,4] are the major weapons
of host defense system against viruses. NAb plays an
important role in preventing the spread of cell-free virus in
vivo [1,2]. Previous studies had shown that passive immu-
nization of non-human primates with high titers of NAbs
could protect non-human primates from SHIV challenge
[5,6]. Currently, the study interest is focusing on the
development of envelop-based vaccines that might elicit
high titers of broadly, long-lasting NAbs [1,7]. The assay
for evaluating NAb is a key tool, and is widely used in
AIDS vaccine research and other experimental and clinical
studies.
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For detection of anti-HIV-1 neutralizing antibody, there
are many methods used today, for example, vital dye
staining [8], p24 antigen determination [9], polymerase
chain reaction [10], flow cytometry [11], reverse tran-
scriptase determination, luciferase activity assay, and so
on. Among them, p24 antigen determination is widely
used in many laboratories, but high cost limits its applica-
tion. The vital dye staining can be used for neutralization
of laboratory T cell line adapted (TCLA) HIV-1 strains,
rather than primary HIV-1 isolates [8]. Because of its low
cost, it is widely used in developing countries. In present
study, we reported an improved, simple, highly duplica-
ble, cost-effective, and well reliable microtiter neutraliza-
tion assay for evaluating HIV-1 neutralizing antibody
from sera or plasma.
Methods
Cells and virus culture
An HTLV-1-transformed human T lymphocyte cell line,
C8166, was used as the host cell for the microtiter neutral-
ization assay. High-titer HIV-1 IIIB stock were obtained by
H9/ HIV-1 IIIB cultures. The 50% tissue culture infectious
dose (TCID50) of the virus stock was determined by end-
point titration on C8166 cells [12]. Clones of C8166 and
H9/ HIV-1 IIIB cell lines were donated from Medical
Research Council (MRC), AIDS Reagent Project. All cul-
tures were grown and maintained in RPMI 1640 medium
supplemented with 15% heat-inactivated fetal calf serum.
Plasma and sera
HIV-1 positive plasma YN02 and YN06 were obtained
from HIV-1 infected asymptomatic individuals, and
DH05, DH11, DH12 and DH16 were collected from HIV-
1 infected injection drug users. Sera S1 and S2 were
obtained from two rabbits immunized with a vaccine
composed of HIV-1 non-gag multi-antigen-epitope pep-
tides, and serum S6 was obtained from normal rabbit as
negative control. All plasma and sera were heat-inacti-
vated at 56°C for 45 min prior to assay.
MTT Assay for detecting the effect of unknown factors in 
plasma on cell growth
Six twofold serial dilutions of HIV-1 positive plasma were
made in duplicate in a total 100 µl of growth medium per
well in 96-well U-bottom plate. The serial dilutions
ranged from 1:4 to 1:128. Then 4 × 104 dispersed C8166
cells in the logarithmic phase in 100 µl of growth medium
were added into each well. Three experimental plates were
prepared. The first plate was washed with growth medium
twice after initial 6 h culture, the second plate was washed
after overnight culture, and the third plate was continu-
ously cultured without any cell washing process. Cell pro-
liferation was measured by MTT (Sigma, Louis, Mo.) assay
as previously described [13]. Briefly, after being cultured
for 6 days, half of the C8166 cell suspension was dis-
carded and 20 µl MTT solution (5 mg/ml in PBS) per well
was added. After another 4–5 h incubation, 100 µl solu-
tion containing 20% SDS plus 50% DMF was added to
melt formazan crystal. The OD values were read at 590
nm wavelength. The cell proliferation indices were calcu-
lated by the OD value in plasma or sera wells (cells plus
plasma or sera) divided by the OD value in cell control
wells (cells only), and then multiplied by 100.
Microtiter assay for HIV neutralizing antibody
Cell-free HIV-1IIIB and serial dilutions of the test plasma
or sera were incubated in duplicate or triplicate for 1 h at
37°C, 5% CO2 incubator before the addition of C8166
cells (4 × 104/well). Virus inoculum was approximately
8,000 TCID50 per well. To determine the optimal time
point for washout procedure, four 96-well U bottom
plates were used for each experiment of plasma YN02,
YN06 and DH11-3. Of them, three plates were washed
with growth medium twice after initial 3 h, 6 h and over-
night (>12 h) culture respectively, and another was cul-
tured without washout procedure. For plasma DH05-1,
DH12-2, DH12-3 and DH16-1, two separate experimen-
tal plates for each plasma sample were prepared. One
plate was washed with medium twice after initial 6 h cul-
ture, while another plate was not washed. After 6-day cul-
ture cytolysis occurred in approximately 80% of C8166
cells in virus control wells, MTT assay was performed as
described above. Protection rate (%) was determined by
the following formula:
The relationship between the number of C8166 cells and  MTT staining Figure 1
The relationship between the number of C8166 cells and 
MTT staining.
Mean OD Mean OD
Mean
(cells   plasma   virus) (cells   virus) ++ + −
   OD  Mean OD (cells) (cells   virus) −
×
+
100BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/30
Page 3 of 6
(page number not for citation purposes)
P24 antigen determination for anti-HIV-1 neutralization 
assay
The p24 antigen determination used for neutralization
assay was performed according to Mascola's method with
minor modification [9]. In present assay, human T cell
line C8166 was used as host cells instead of peripheral
blood mononuclear cells (PBMC), and HIV-1IIIB as virus
inoculum. Briefly, the neutralization assay of sera S1, S2,
plasma YN06 and negative control serum S6 at four three-
fold serial dilutions was performed using approximate
5,000 TCID50 HIV-1IIIB virus inoculum for each well.
After 6 h culture, the U-bottom plate was washed with
growth medium thrice to completely remove both the free
virus inoculum and all the residual anti-p24 antibodies
from the serum or plasma. Two days later, 10 µl culture
supernatant was collected from each well for quantifying
the p24 antigen production. The quantification of p24
antigen was carried out using RETRO-TEK HIV-1 p24
ELISA (ZeptoMetrix Corporation, New York) according to
the manufacturer's instructions. Percent protection was
determined by calculating the reduction in p24 produc-
tion relative to the virus control [9]. Another four days
later, MTT assay was performed as described above.
Results and discussion
MTT as the vital dye
MTT [14] and neutral red (NR) [15] are well known vital
dyes used in the cell viability assay. In previous microtiter
neutralization assay, NR was used as the vital dye [8]. In
our experience, however, NR appears to have poor solu-
bility in growth medium or RPMI-1640 medium. On the
other hand, when NR is used, the microtiter neutraliza-
tion assay needs a series of complex experimental proc-
esses including coating plate with poly-L-lysine (PLL),
adhering cells to PLL-coated plate, washout procedure,
extracting NR from cells, and so on [8]. In contrast to NR,
MTT has a good solubility, and MTT assay has a relatively
simple experimental process [13,14]. Therefore, we used
MTT as the vital dye in our microtiter neutralization assay.
Fig. 1 showed an excellent linear relationship (r = 0.9307;
The effect of plasma on C8166 cell growth Figure 2
The effect of plasma on C8166 cell growth. Tested plasma were maintained in the continuous culture or were removed by 
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P < 0.0001) between the numbers of the C8166 cells in
the range of 1.95 × 103 to 5 × 105 per well and MTT
staining.
The unknown factors in tested plasma or sera affected cell 
growth
Previously, tested human plasma or sera were maintained
in the whole cell culture of microtiter neutralization assay.
We found that the unknown factors in tested human
plasma YN02 and YN06 stimulated the growth of host
cells and resulted in overestimate of HIV-1 neutralization
when the tested plasma were maintained in whole assay
(Fig. 2). In contrast, the unknown factors in some other
clinical plasma (such as DH05-1 and DH11-3) surpris-
ingly inhibited cell growth dramatically at high concentra-
tion (Fig. 2). In order to eliminate these effects, we washed
host cells with medium after initial 6 h or overnight cul-
ture. The results showed that washout procedure effec-
tively decreased or eliminated these adverse effects of the
factors in tested plasma (Fig. 2), suggesting that some
unknown factors in these clinical plasma might be
responsible for the stimulation or inhibition of cell
growth.
The unknown factors in tested plasma caused inaccurate 
anti-HIV-1 protection using previous microtiter 
neutralization assay
The microtiter neutralization assay was established on the
base of the quantification of virus-induced extensive
cytolysis of host cells [8], the unknown factors in clinical
plasma affects cell growth, and therefore lead to inaccu-
rate determination of HIV-1 neutralization. To testify the
hypothesis, HIV-1 neutralization by these clinical human
plasma was determined using previous microtiter neutral-
ization assay. When tested plasma was maintained in
whole assay, the plasma at dilution of 1:4 (such as YN02
and YN06) stimulated cell growth, their protection rates
distinctly were beyond 100% (Fig. 3). On the contrary, the
plasma DH05-1 at dilution of 1:4 inhibited cell growth,
appeared to have no protection, which was much lower
than at higher dilutions (Fig. 4A). The above overestima-
tion or underestimation of anti-HIV-1 protections at high
plasma concentration suggested that previous method
was unable to accurately evaluate anti-HIV-1 neutraliza-
tion of clinical human plasma, and the elimination of
these plasma effects is necessary for microtiter neutraliza-
tion assay.
Determination of the optimal time point for washout procedure in the improved microtiter neutralization assay Figure 3
Determination of the optimal time point for washout procedure in the improved microtiter neutralization assay. Tested plasma 
were maintained in the continuous culture or were removed by washout procedure after initial 3 h, 6 h and overnight culture 
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Optimal time point for removing the unknown factors
In order to eliminate the effect of the factors on HIV-1
neutralization assay, we removed the factors from cell cul-
ture system by adding a washout procedure at 3 h, 6 h and
overnight after culture. We found that washout after both
initial 3 h and 6 h culture resulted in consistent protection
rates at various dilutions of tested plasma (Fig. 3: YN02
and YN06), suggesting that washout after initial 3 to 6 h
culture could completely eliminate the effect of the
unknown factors in plasma on anti-HIV-1 neutralization
assay.
Anti-HIV-1 neutralization of plasma YN05-1, DH12-2,
DH12-3 and DH16-1, which inhibited distinctly cell
growth at high concentration, was determined using the
improved microtiter neutralization assay. The results
showed that the underestimation of HIV-1 protection
rates obtained by previous method were corrected (Fig.
4B). These results suggested the improved assay was able
to eliminate both the effect of the unknown factors in
plasma (or sera) on anti-HIV-1 neutralization and pro-
long time exposure cells to virus and plasma (or sera).
The comparison between the improved microtiter 
neutralization assay and p24 antigen neutralization assay
P24 antigen assay was widely used for evaluating HIV-1
NAb by detecting the reduction of p24 antigen production
caused by NAbs [9]. To detect the reliability of the
improved microtiter neutralization assay, both assays
were performed with the same host cells, cell densities
and virus inoculum. The results showed an excellent
agreement of the protection rate in both assays (Fig. 5),
suggesting the improved microtiter neutralization assay is
as sensitive and reliable as p24 antigen determination in
evaluating HIV-1 NAbs from sera or plasma.
Conclusion
Currently, HIV-1 neutralization assay is a key tool, and is
widely used in AIDS vaccine research and other experi-
mental and clinical studies. Because of cost considera-
tions, the vital dye staining method, such as previous
microtiter neutralization assay [8], is widely accepted in
many laboratories. However, previous assay neglected the
effect of the unknown factors in some tested plasma or
sera on cell growth, and might lead to inaccurate anti-
HIV-1 neutralization. Here, we modified the previous
microtiter neutralization assay by using MTT as vital dye
and by removing the factors in tested plasma or sera. In
comparison with the other methods, the improved
method increased the reliability of anti-HIV-1 neutraliza-
tion assay for plasma or sera, and is relatively simple,
highly duplicable, cost-effective for evaluating anti-HIV-1
neutralizing antibody from sera or plasma.
Competing interests
None declared.
The anti-HIV-1 neutralizing activities of various patient  plasma were measured by the previous microtiter neutraliza- tion assay (A) and by the improved microtiter neutralization  assay (B) Figure 4
The anti-HIV-1 neutralizing activities of various patient 
plasma were measured by the previous microtiter neutraliza-
tion assay (A) and by the improved microtiter neutralization 
assay (B).
The comparison of the anti-HIV-1 neutralizing activities of  some samples detected by the modified improved neutraliza- tion assay (A) with those by p24 neutralization assay (B) Figure 5
The comparison of the anti-HIV-1 neutralizing activities of 
some samples detected by the modified improved neutraliza-
tion assay (A) with those by p24 neutralization assay (B).Publish with BioMed Central    and   every 
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